Swedish biotech Alligator Bioscience outlines how strategic antibody engineering and focused execution positioned mitazalimab for pivotal trials in metastatic pancreatic cancer, transforming from university research into a Phase 3-ready immunotherapy program. Founded in 2001 and headquartered in Lund, Sweden, Alligator
Addressing an Aggressive Pediatric Disease with No Treatment Options Spanish biotech Minoryx has carved out a critical position in orphan CNS diseases by developing leriglitazone for X-linked adrenoleukodystrophy (X-ALD), a genetic condition where patients in the most aggressive phenotype face
“When you are seeing great results in your research lab, you think that everything has been done. But then when you try to humanise your drug, a new adventure starts, because the CMC process is very difficult. In my opinion,
“There are not that many European CDMOs with commercial expertise in cell therapy – who understand the regulatory requirements and production challenges when you have to manufacture large quantities on a regular basis. This is why we ended up with
